How Third-Party Audits Can Help Ensure Excipient Quality

News
Article

Audits by independent experts promise to ease the burden that customer audits can have on suppliers, while ensuring drug manufacturers that ingredients meet strict cGMP standards.

Today, a growing number of compliance and quality failures can be traced to problems with API and excipient manufacturing. Finished drug manufacturers must be sure that the ingredients used in their products meet current good manufacturing standards, but the expense and time required for audits can be a significant burden. From the ingredient supplier’s perspective as well, having pharmaceutical customers conduct thorough audits of their facilities can pose serious challenges. One solution that the world’s regulatory agencies are supporting is having experts from independent authorities conduct these audits and provide certificates of compliance.

 

Sessions at CPhI will discuss pharmaceutical and raw material quality in great depth from Oct. 9–11, 2018 in Madrid, Spain. For more information on third-party inspection and certification, this article from Pharmaceutical Technology’sSeptember supplement on pharmaceutical materials, written by experts affiliated with the International Pharmaceutical Excipients Council (IPEC) outlines how the practice works, what is required, and the benefits it offers (1).

 

Reference

 

1. D.B. Klug, R.D. Lindblad, D.G. Muse, K. L. Ulman, P. Walsh, and P.S. Zawislak, Pharmaceutical Technology APIs, Excipients, & Manufacturing 2018 (September 2018).

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes